Mechanism of Kaixin Powder prescriptions Buxin Decoction regulating PI3K/AKT signaling pathway to protect cardiovascular system: based on network pharmacology and experimental verification.
10.19540/j.cnki.cjcmm.20220613.709
- Author:
Xia LI
1
;
Yuan-Bo WANG
1
;
Chao-Chen WANG
1
;
Xin LI
2
;
Yuan HU
2
Author Information
1. Graduate School, Chinese PLA General Hospital Beijing 100089, China Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital Beijing 100089, China.
2. Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital Beijing 100089, China.
- Publication Type:Journal Article
- Keywords:
Buxin Decoction;
Kaixin Powder prescriptions;
PI3K/AKT signaling pathway;
cardiac protection;
myocardial ischemia
- MeSH:
Rats;
Animals;
Proto-Oncogene Proteins c-akt/metabolism*;
Phosphatidylinositol 3-Kinases/metabolism*;
Powders;
Network Pharmacology;
Signal Transduction;
Myocardial Ischemia;
Myocardium/pathology*;
Creatine Kinase;
Interleukin-6/metabolism*;
Tumor Necrosis Factor-alpha/metabolism*;
Prescriptions
- From:
China Journal of Chinese Materia Medica
2022;47(21):5916-5925
- CountryChina
- Language:Chinese
-
Abstract:
This study established the EA.hy926 cell myocardial ischemia model to compare the effects of two Kaixin Powder prescriptions, Buxin Decoction(BXD) and Dingzhi Pills(DZP), at three dosages(500, 200, and 100 μg·mL~(-1)) on the cell viability. Further, the public databases(TCMSP, TCMID, SYMMAP, and STRING) and the network pharmacology methods such as KEGG pathway enrichment were employed to decipher the possible molecular mechanism of BXD in exerting the cardioprotective effect. The pharmacological effect of BXD was evaluated with the rat model of isoprenaline(ISO)-induced myocardial ischemia. The expression levels of proteins involved in the phosphatidylinositol-3-kinase/protein kinase B(PI3 K/AKT) signaling pathway were measured by Western blot. BXD significantly increased the viability of EA.hy926 cells, showing the performance superior to DZP. The network pharmacology analysis predicted that BXD might exert cardiac protection through the PI3 K/AKT signaling pathway. The in vivo experiment on rats showed that BXD treatment significantly increased the cardiac ejection fraction(EF), fractional shortening(FS), diastolic left ventricular anterior wall(LVAWd), systolic left ventricular anterior wall(LVAWs), and diastolic left ventricular posterior wall(LVPWd), significantly decreased the beat per minute(BPM) and diastolic left ventricular internal diameter(LVIDd), and significantly improved the ST segment in the electrocardiogram. The pathological results(Masson staining) showed that BXD restored the myocardial thickness, decreased the collagen fiber, increased the muscle fiber, and reduced the infarct area to alleviate myocardial ischemia. Furthermore, BXD lowered the serum levels of inflammatory cytokines [tumor necrosis factor-α(TNF-α) and interleukin-6(IL-6)] and myocardial enzymes [creatine kinase(CK) and lactate dehydrogenase(LDH)], increased the p-AKT/AKT ratio, up-regulated the protein levels of PI3 K, NF-κB, IKK-α, and Bcl-xl, and down-regulated that of the apoptotic protein Bax. In conclusion, BXD may exert cardiac protection effect by regulating the PI3 K/AKT signaling pathway.
